- Home
- FC vs CDTX Comparison
FC vs CDTX Comparison
Compare FC & CDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FC
- CDTX
- Stock Information
- Founded
- FC 1983
- CDTX 2012
- Country
- FC United States
- CDTX United States
- Employees
- FC N/A
- CDTX N/A
- Industry
- FC Other Consumer Services
- CDTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FC Consumer Discretionary
- CDTX Health Care
- Exchange
- FC Nasdaq
- CDTX Nasdaq
- Market Cap
- FC 279.6M
- CDTX 269.8M
- IPO Year
- FC 1992
- CDTX 2015
- Fundamental
- Price
- FC $23.20
- CDTX $19.36
- Analyst Decision
- FC Strong Buy
- CDTX Strong Buy
- Analyst Count
- FC 2
- CDTX 8
- Target Price
- FC $42.50
- CDTX $38.50
- AVG Volume (30 Days)
- FC 84.5K
- CDTX 93.7K
- Earning Date
- FC 06-25-2025
- CDTX 05-08-2025
- Dividend Yield
- FC N/A
- CDTX N/A
- EPS Growth
- FC 8.95
- CDTX N/A
- EPS
- FC 1.34
- CDTX N/A
- Revenue
- FC $286,195,000.00
- CDTX $302,000.00
- Revenue This Year
- FC N/A
- CDTX N/A
- Revenue Next Year
- FC $5.25
- CDTX N/A
- P/E Ratio
- FC $17.38
- CDTX N/A
- Revenue Growth
- FC 2.53
- CDTX N/A
- 52 Week Low
- FC $18.94
- CDTX $10.14
- 52 Week High
- FC $44.46
- CDTX $28.42
- Technical
- Relative Strength Index (RSI)
- FC 57.43
- CDTX 44.76
- Support Level
- FC $20.10
- CDTX $18.51
- Resistance Level
- FC $21.79
- CDTX $20.97
- Average True Range (ATR)
- FC 0.69
- CDTX 1.39
- MACD
- FC 0.59
- CDTX -0.18
- Stochastic Oscillator
- FC 88.20
- CDTX 19.91
About FC Franklin Covey Company
Franklin Covey Co is a company focused on organizational performance improvement. It focuses on providing time management and effectiveness training for individuals and corporations via online training as well as in-person workshops and events. The company provides training and consulting services in the areas of leadership, execution, productivity, trust, sales performance, customer loyalty, and educational improvement. It operates in the business segments of Direct Offices, Education division, and International Licensees. The company derives revenue from providing training and consulting services, and through the selling of books, audio media, and other related products. It has a business presence in the Australia, New Zealand, China, Japan, United Kingdom, Ireland, and Other countries.
About CDTX Cidara Therapeutics Inc.
Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. Its clinical-stage asset is CD388, a DFC intended for influenza prophylaxis. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.